Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol
The estrogen receptors (ERs) belong to the nuclear receptor superfamily, and as such act as ligand inducible transcription factors, mediating the effects of estrogens. However, their pharmacology is complex, having the ability to be differentially activated by ligands. Such ligands possess the ability to behave as either ER-agonists or ER-antagonists, depending on the cellular and tissue context, and have been termed Selective Estrogen Receptor Modulators (SERMs). Several SERMs have been identified with clinical relevance such as tamoxifen and raloxifene. Recently, 27-hydroxycholesterol has been characterized as the first ...
Source: Springer protocols feed by Biochemistry - October 11, 2015 Category: Biochemistry Source Type: news
Aurobindo Pharma gets US FDA nod for generic osteoporosis drug
Aurobindo Pharma has received approval from the US FDA to manufacture and market its generic version of Eli Lilly's Evista tablets used to treat and prevent osteoporosis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 29, 2015 Category: Pharmaceuticals Source Type: news
Some 'Benign' Breast Masses Pose Greater Cancer Risk Than We Thought
By Gene Emery (Reuters Health) - A type of "benign" mass found in the breast tissue of about 100,000 U.S. women each year poses a greater risk of cancer than previously thought, according to a new review. The mass is classified as atypical hyperplasia, or atypia. Most women who have it - and one out of 10 women who have a breast biopsy do - are usually told that their test result was benign, even though their cells seemed to be exhibiting some early characteristics of a tumor. Doctors may tell those women that they face an above-average risk of cancer so they need to be ...
Source: Healthy Living - The Huffington Post - December 31, 2014 Category: Consumer Health News Source Type: news
One million women denied 7p breast cancer drug that can halve chance of developing disease
One million women have been denied pills that could reduce chances of developing breast cancer. Tamoxifen, Raloxifene and Anastrozole have not been licensed for preventative use. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news
One million women denied the 7p breast cancer drug that can halve chance of developing disease because of red tape
One million women have been denied pills that could reduce chances of developing breast cancer. Tamoxifen, Raloxifene and Anastrozole have not been licensed for preventative use. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news
Review Examines Efficacy and Safety of Osteoporosis Drugs (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Bisphosphonates, denosumab, teriparatide, and raloxifene all reduce risk for fracture relative to placebo in women with osteoporosis, according to a federally commissioned systematic review … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 9, 2014 Category: Primary Care Source Type: news
Revealing novel mode of action for osteoporosis drug
Raloxifene is a US Food and Drug Administration-approved treatment for decreasing fracture risk in osteoporosis. While raloxifene is as effective at reducing fracture risk as other current treatments, this works only partially by suppressing bone loss. X-ray studies revealed an additional mechanism underlying raloxifene action, providing an explanation for how this drug can achieve equivalent clinical benefit. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 29, 2014 Category: Science Source Type: news
Revealing a novel mode of action for an osteoporosis drug
(DOE/Argonne National Laboratory) Raloxifene is a US Food and Drug Administration-approved treatment for decreasing fracture risk in osteoporosis. While raloxifene is as effective at reducing fracture risk as other current treatments, this works only partially by suppressing bone loss. X-ray studies revealed an additional mechanism underlying raloxifene action, providing an explanation for how this drug can achieve equivalent clinical benefit. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 29, 2014 Category: Global & Universal Source Type: news
500,000 denied 7p-a-day breast cancer drug
Those with a family history of breast cancer should be offered Tamoxifen or the similar drug Raloxifene, which can cut their risk by 40 per cent. (Source: the Mail online | Health)
Source: the Mail online | Health - July 2, 2014 Category: Consumer Health News Source Type: news
Deirdre Connelly
President, North American Pharmaceuticals Deirdre Connelly joined GSK as President, North American Pharmaceuticals, on 9
February 2009. She reports to Andrew Witty, Chief Executive Officer and is a member of GSK’s Corporate Executive Team.
Prior to this, Deirdre was appointed President of US operations at Eli Lilly and Company in 2005. Previously she was senior vice president for Human Resources for Lilly. She had joined Lilly in 1983 as a sales representative and moved to San Juan as a marketing associate a year later. After progressing through sales and marketing roles of increasing responsibility, including Li...
Source: PHRMA - April 7, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
Teva's Generic Evista Approved In The U.S.
Teva announced that its generic equivalent to Evista (raloxifene) 60 mg tablets has been approved in the U.S. The approval makes Teva’s generic version eligible for 180 days of marketing exclusivity. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 10, 2014 Category: Pharmaceuticals Source Type: news
Teva Announces Approval of Generic Evista(R) Tablets 60 mg in the United States
JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd. (TEVA) announces the approval of the generic equivalent to Evista® (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product elig... Biopharmaceuticals, Generics, FDA, Product LaunchTeva Pharmaceutical, Evista, Raloxifene (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 4, 2014 Category: Pharmaceuticals Source Type: news
Evista (Raloxifene HCI) Lowers Risk of Invasive...
Evista (raloxifene) is a drug that has been used for treatment of osteoporosis in postmenopausal women. The FDA has also approved it for prevention of invasive breast cancer. Evista creates an estrogen blockade, which lowers the incidence of estrogen-sensitive breast cancer. Learn more about Evista - uses, side effects, and benefits. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 21, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Women who could benefit from medicine to prevent breast cancer often don't take them
Many new and potent medicines to prevent breast cancer have become available in the past 20 years. Surprisingly, many women—even those at high risk for the disease—are not taking advantage of these medicines, according to an article in the January 2014 issue of the Harvard Women's Health Watch.
Drugs such as tamoxifen (Nolvadex), raloxifene (Evista), and exemestane (Aromasin) can reduce the odds of developing breast cancer for many women at high risk of developing breast cancer. "These drugs have been shown to prevent the occurrence of invasive and pre-invasive breast cancers," says Dr. Paul Goss, director of b...
Source: New Harvard Health Information - December 20, 2013 Category: Consumer Health News Source Type: news
Anastrozole may cut breast cancer risk
Conclusion
Overall, the study provides solid and believable evidence that anastrozole can reduce the number of new cases of breast cancer in postmenopausal women at higher than average risk of developing breast cancer.
The study has many strengths, including its large sample size and robust study design. However, the study also has limitations to note.
The results only apply to a specific group of postmenopausal women at a higher than average risk of developing breast cancer. "Higher risk" was defined using a number of very specific criteria. This means the results are not applicable to other groups of postmeno...
Source: NHS News Feed - December 13, 2013 Category: Consumer Health News Tags: Cancer Medication Source Type: news
